Ретроперитонеальный фиброз: современный взгляд на старую патологию или когда вопросов больше, чем ответов
https://doi.org/10.47360/1995-4484-2026-133-140
Аннотация
Ретроперитонеальный фиброз, или болезнь Ормонда, – редкое хроническое заболевание неустановленной этиологии, характеризующееся прогрессирующим разрастанием неопухолевой фиброзно-воспалительной ткани в забрюшинном пространстве с типичной ее локализацией в инфраренальном отделе аорты с переходом на подвздошные сосуды и вовлечением в патологический процесс мочеточников и других органов забрюшинного пространства. Заболевание нередко протекает с развитием острого мочевого блока, что в ряде случаев связано с поздней диагностикой ввиду низкой осведомленности специалистов. Настоящий обзор посвящен описанию клинических особенностей, эпидемиологии и патогенеза заболевания. Рассмотрены современные подходы к диагностике и лечению, приведены актуальные данные литературы. Работа носит описательный характер и служит обзором существующих знаний в данной области.
При поддержке: Статья подготовлена в рамках фундаментальной темы № 125020501434-1
Об авторах
А. С. Веретенников
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Конфликт интересов:
Россия
Веретенников Алексей Сергеевич
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
нет
А. В. Торгашина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Конфликт интересов:
Россия
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
нет
Список литературы
1. Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol. 1948;59(6):1072-1079. doi: 10.1016/S0022-5347(17)69482-5
2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732-738. doi: 10.1056/NEJM200103083441005
3. Hamano H, Kawa S, Ochi Y, Unno H, Shiba N, Wajiki M, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet. 2002;359(9315):1403-1404. doi: 10.1016/s0140-6736(02)08359-9
4. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21-30. doi: 10.1007/s10165-011-0571-z
5. Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72(1):7-19. doi: 10.1002/art.41120
6. Maritati F, Rocco R, Accorsi Buttini E, Marvisi C, Nicastro M, Urban ML, et al. Clinical and prognostic significance of serum IgG4 in chronic periaortitis. An analysis of 113 patients. Front Immunol. 2019;10:693. doi: 10.3389/fimmu.2019.00693
7. Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med. 2017;12(3):287-299. doi: 10.1007/s11739-016-1599-z
8. Wang K, Wang Z, Zeng Q, Zhu L, Gao J, Wang Z, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One. 2021;16(2):e0245601. doi: 10.1371/journal.pone.0245601
9. Tanaka T, Masumori N. Current approach to diagnosis and management of retroperitoneal fibrosis. Int J Urol. 2020;27(5):387-394. doi: 10.1111/iju.14218
10. Alberti C. Drug-induced retroperitoneal fibrosis: Short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology. G Chir. 2015;36(4):187-191. doi: 10.11138/gchir/2015.36.4.187
11. Shebani MAA, Ikdees AA, Alazeebi SY, Nagib E, Alagha HMK. A multifactorial case of retroperitoneal fibrosis in a post-radiation bladder cancer patient: Diagnostic and therapeutic challenges. Cureus. 2025;17(8):e89976. doi: 10.7759/cureus.89976
12. Wang J, Hu S, Zhang P, Wu H. Idiopathic retroperitoneal fibrosis associated with a rare case of multifocal tuberculosis. J Clin Rheumatol. 2021;27(8S):S652-S653. doi: 10.1097/RHU.0000000000001646
13. Rollino C, Guzman H, Beltrame G, Ferro M, Quattrocchio G, Bellis D, et al. Retroperitoneal fibrosis and schistosomiasis: A causal relationship? Eur J Intern Med. 2008;19(4):297-299. doi: 10.1016/j.ejim.2007.06.021
14. Zhang L, Zhan S. Encased by infection: A rare case of retroperitoneal fibrosis induced by disseminated cysticercosis. Case Rep Infect Dis. 2025;2025:6221398. doi: 10.1155/crdi/6221398
15. Salliot C, Lavie F, Azria A, Clerc D, Miquel A, Mariette X. Retroperitoneal fibrosis secondary to spondylodiscitis after infection with Prevotella. J Rheumatol. 2005;32(5):957-958.
16. Yague M, Temprano I, Losa J, De Benito L, De La Cruz R, Cheyne N, et al. Staphylococcus aureus aortitis and retroperitoneal fibrosis: A case report and literature review. IDCases. 2016;5:60-62. doi: 10.1016/j.idcr.2016.07.010
17. Rodríguez-Hernández MJ, Viciana P, Cordero E, López-Cortés LF, Pachón J. Retroperitoneal fibrosis in a patient with human immunodeficiency virus infection. Arch Intern Med. 1998;158(3):301-302. doi: 10.1001/archinte.158.3.301
18. Lee SJ, Eun JS, Kim MJ, Song YW, Kang YM. Association of retroperitoneal fibrosis with malignancy and its outcomes. Arthritis Res Ther. 2021;23(1):249. doi: 10.1186/s13075-021-02627-3
19. Gil A, Ofer Y, Yigla M, Goralnik L, Meretyk S, Assady S. Obstructive uropathy caused by retroperitoneal fibrosis presents as a late manifestation of sarcoidosis. Ren Fail. 2010;32(9):11181120. doi: 10.3109/0886022X.2010.510612
20. Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, et al. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol. 2025;21(5):275-290. doi: 10.1038/s41584-025-01240-x
21. Katz R, Golijanin D, Pode D, Shapiro A. Primary and postoperative retroperitoneal fibrosis-experience with 18 cases. Urology. 2002;60(5):780-783. doi: 10.1016/s0090-4295(02)01910-6
22. Uibu T, Oksa P, Auvinen A, Honkanen E, Metsärinne K, Saha H, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet. 2004;363(9419):1422-1426. doi: 10.1016/S0140-6736(04)16100-X
23. Goldoni M, Bonini S, Urban ML, Palmisano A, De Palma G, Galletti E, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: A case-control study. Ann Intern Med. 2014;161(3):181-188. doi: 10.7326/M13-2648
24. Boiardi L, Vaglio A, Nicoli D, Farnetti E, Palmisano A, Pipitone N, et al. CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology (Oxford). 2011;50(6):1025-1032. doi: 10.1093/rheumatology/keq416
25. Pipitone N, Vaglio A, Salvarani C. Retroperitoneal fibrosis. Best Pract Res Clin Rheumatol. 2012; 26(4):439-448. doi: 10.1016/j.berh.2012.07.004
26. Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol. 1994;47(8):721-727. doi: 10.1136/jcp.47.8.721
27. Urban ML, Palmisano A, Nicastro M, Corradi D, Buzio C, Vaglio A. Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. Rev Med Interne. 2015;36(1):15-21. doi: 10.1016/j.revmed.2014.10.008
28. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241-251. doi: 10.1016/S0140-6736(06)68035-5
29. Cai S, Hu Z, Chen Y, Zhong J, Dong L. Potential roles of nonlymphocytic cells in the pathogenesis of IgG4-related disease. Front Immunol. 2022;13:940581. doi: 10.3389/fimmu.2022.940581
30. Hu JQ, Jin ZY, Yu YY, Min DM, Cai Q, Gao J. Clinical characteristics of IgG4-related retroperitoneal fibrosis in a cohort of 117 patients with idiopathic retroperitoneal fibrosis: A retrospective study. Clin Rheumatol. 2025;44(2):757-766. doi: 10.1007/s10067-024-07276-w
31. van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse ALHJ. Idiopathic retroperitoneal fibrosis: Prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). 2009;88(4):193-201. doi: 10.1097/MD.0b013e3181afc420
32. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: A case series. Ann Intern Med. 2011;154(1):31-36. doi: 10.7326/0003-4819-154-1-201101040-00005
33. Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: The clinical, laboratory, and radiographic presentation. Medicine (Baltimore). 2009;88(4):202-207. doi: 10.1097/MD.0b013e3181afc439
34. Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial. Lancet. 2011;378(9788):338-346. doi: 10.1016/S0140-6736(11)60934-3
35. Zhao J, Li J, Zhang Z. Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: A retrospective study. Scand J Rheumatol. 2019;48(3):239-245. doi: 10.1080/03009742.2018.1497700
36. Palmisano A, Cobelli R, Buzio C, Vaglio A. Peri-renal collateral circles. Urology. 2009;74(2):292-293. doi: 10.1016/j.urology.2009.02.052
37. Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 2016;27(7):1880-1889. doi: 10.1681/ASN.2015101110
38. Akbal C, Tanidir Y, Ozgen MB, Simşek F. Erectile dysfunction and Peyronie’s disease in patient with retroperitoenal fibrosis. Int Urol Nephrol. 2008;40(4):971-975. doi: 10.1007/s11255-008-9381-4
39. Huang Z, Liu Y, Xiao Y, Hu H, Xu T. Idiopathic retroperitoneal fibrosis-related hydronephrosis: Evaluation of comprehensive management and prediction of inflammatory markers for stent-free outcomes. Int J Gen Med. 2025;18:113-121. doi: 10.2147/IJGM.S490245
40. Tani T, Ishihara C, Kaneko T, Tsuruoka S, Iino Y. Multiple cerebral lesions as the unique complication of idiopathic retroperitoneal fibrosis. Mod Rheumatol. 2015;25(3):468-471. doi: 10.3109/14397595.2013.843754
41. Salvarani C, Calamia KT, Matteson EL, Hunder GG, Pipitone N, Miller DV, et al. Vasculitis of the gastrointestinal tract in chronic periaortitis. Medicine (Baltimore). 2011;90(1):28-39. doi: 10.1097/MD.0b013e318207231e
42. Palmisano A, Urban ML, Corradi D, Cobelli R, Alberici F, Maritati F, et al. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: A systemic large vessel vasculitis? Rheumatology (Oxford). 2015;54(11):2004-2009. doi: 10.1093/rheumatology/kev225
43. Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acutephase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. 2009;61(5):674-679. doi: 10.1002/art.24461
44. Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EF. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. 2012;27(7):2819-2825. doi: 10.1093/ndt/gfr779
45. Stone JH. IgG4-related disease: Lessons from the first 20 years. Rheumatology. 2025;64(Suppl 1):i24-i27. doi: 10.1093/rheumatology/keaf008
46. Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S, et al.; Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31(3):529-533. doi: 10.1080/14397595.2020.1859710
47. Wallace ZS, Mattoo H, Mahajan VS, Kulikova M, Lu L, Deshpande V, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016;55(6):10001008. doi: 10.1093/rheumatology/kev438
48. Moriconi D, Giannese D, Capecchi R, Cupisti A, Barsotti S, Morganti R, et al. Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis. Clin Exp Nephrol. 2019;23(9):1147-1153. doi: 10.1007/s10157-019-01759-w
49. Raffiotta F, da Silva Escoli R, Quaglini S, Rognoni C, Sacchi L, Binda V, et al. Idiopathic retroperitoneal fibrosis: Long-term risk and predictors of relapse. Am J Kidney Dis. 2019;74(6):742-750. doi: 10.1053/j.ajkd.2019.04.020
50. Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: What a hematologist needs to know. Haematologica. 2019;104(3):444-455. doi: 10.3324/haematol.2018.205526
51. Полухина ЕВ, Глазун ЛО. Ультразвуковая диагностика ретроперитонеального фиброза. Ультразвуковая и функциональная диагностика. 2016;5:11-21.
52. Shang J, Liu M, Wang Y, An Y, An L, Li K, et al. Value of contrast-enhanced ultrasonography in assessing the activity of idiopathic retroperitoneal fibrosis: A prospective study. Clin Exp Rheumatol. 2022;40(3):539-543. doi: 10.55563/clinexprheumatol/qie29j
53. Mirault T, Lambert M, Puech P, Argatu D, Renaud A, Duhamel A, et al. Malignant retroperitoneal fibrosis: MRI characteristics in 50 patients. Medicine (Baltimore). 2012;91(5):242-250. doi: 10.1097/MD.0b013e31826b1c1d
54. Accorsi Buttini E, Maritati F, Vaglio A. [18F]-fluorodeoxyglucose positron emission tomography and response to therapy in idiopathic retroperitoneal fibrosis. Eur Urol. 2018;73(1):145-146. doi: 10.1016/j.eururo.2017.09.024
55. Bond M, Bettiol A, Buttini EA, Trivioli G, Palazzini G, Fibbi I, et al. Predictors of remission and relapse in retroperitoneal fibrosis. J Intern Med. 2025;298(5):438-449. doi: 10.1111/joim.70017
56. Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T. [18F]-fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: A prospective clinical study. Eur Urol. 2017;71(6):926-933. doi: 10.1016/j.eururo.2016.10.046
57. Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging. 2012;39(10):1635-1642. doi: 10.1007/s00259-012-2144-6
58. Yilmaz S, Tan YZ, Ozhan M, Halac M, Asa S, Sönmezoglu K. FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol. 2012;31(6):338-339. doi: 10.1016/j.remn.2012.04.001
59. Mishra K, Zargar H, Tarplin S, Ramanathan R, Stein RJ. Idiopathic retroperitoneal fibrosis. J Urol. 2015;193(5):1657-1658. doi: 10.1016/j.juro.2015.01.101
60. Mizushima I, Morikage N, Ito E, Kasashima F, Matsumoto Y, Sawa N, et al.; Joint Working Group from the Japanese Circulation Society and the Ministry of Health, Labour and Welfare Study Group. Validation of the diagnostic criteria for IgG4-related periaortitis/periarteritis and retroperitoneal fibrosis (IgG4PA/RPF) 2018, and proposal of a revised 2023 version for IgG4-related cardiovascular/retroperitoneal disease. Circ J. 2024;88(10):1679-1688. doi: 10.1253/circj.CJ-24-0026
61. Лищук СВ, Дубова ЕА, Павлов КА, Борбат АМ, Удалов ЮД. Клинико-морфологические особенности IgG4-связанного забрюшинного фиброза. Альманах клинической медицины. 2020;48(2):110-116. doi: 10.18786/2072-05052020-48-010
62. Li J, Wang H, Wang M, Xu F, Guo F, Ye F. Differences of clinicopathological features between IgG4-related and non-IgG4-related idiopathic retroperitoneal fibrosis. Int J Rheum Dis. 2022;25(4):440-446. doi: 10.1111/1756-185X.14287
63. Stone JH (ed.). A clinician’s pearls and myths in rheumatology; 2nd ed. Cham:Springer International Publishing AG;2023. doi: 10.1007/978-3-031-23488-0
64. Ross JC., Goldsmith HJ. The combined surgical and medical treatment of retroperitoneal fibrosis. Br J Surg. 1971;58(6):422-427. doi: 10.1002/bjs.1800580606
65. Alexopoulos E, Memmos D, Bakatselos S, Rombis V, Sakellariou G, Gaganakis J, et al. Idiopathic retroperitoneal fibrosis: A long-term follow-up study. Eur Urol. 1987;13(5):313-317. doi: 10.1159/000472808
66. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whitfield HN, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol. 1987;60(6):497-503. doi: 10.1111/j.1464-410x.1987.tb05028.x
67. van Bommel EFH. Retroperitoneal fibrosis. Neth J Med. 2002;60(6):231-242.
68. van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis. 2007;49(5):615-625. doi: 10.1053/j.ajkd.2007.02.268
69. van Bommel EF, van Spengler J, van der Hoven B, Kramer P. Retroperitoneal fibrosis: Report of 12 cases and a review of the literature. Neth J Med. 1991;39(5-6):338-345.
70. Kardar AH, Kattan S, Lindstedt E, Hanash K. Steroid therapy for idiopathic retroperitoneal fibrosis: Dose and duration. J Urol. 2002;168(2):550-555.
71. Alberici F, Palmisano A, Urban ML, Maritati F, Oliva E, Manenti L, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013;72(9):1584-1586. doi: 10.1136/annrheumdis-2013-203267
72. Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: A long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis. 2012;71(2):311-312. doi: 10.1136/annrheumdis-2011-200148
73. Grotz W, von Zedtwitz I, Andre M, Schollmeyer P. Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet. 1998;352(9135):1195. doi: 10.1016/S01406736(05)60533-8
74. Jois RN, Kerrigan N, Scott DG. Mycophenolate mofetil for maintenance of remission in idiopathic retroperitoneal fibrosis. Rheumatology (Oxford). 2007;46(4):717-718. doi: 10.1093/rheumatology/kel417
75. Peyronel F, Palmisano A, Maritati F, Alberici F, Urban ML, Gianfreda D, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: A randomised clinical trial. J Autoimmun. 2025;157:103487. doi: 10.1016/j.jaut.2025.103487
76. Vianello F, Romano Gargarella L, Cinetto F, Scarpa R, Ceccato J, Marcolongo R. Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2023;41(7):15441547. doi: 10.55563/clinexprheumatol/atxzl5
77. Yunyun F, Yu C, Panpan Z, Hua C, Di W, Lidan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep. 2017;7(1):6195. doi: 10.1038/s41598-017-06520-5
78. Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z, et al. Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease: A randomized clinical trial. Rheumatology (Oxford). 2019;58(1):52-60. doi: 10.1093/rheumatology/key227
79. Boyeva V, Alabsi H, Seidman MA, Paterson R, Kur J, Chen LYC, et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol. 2020;4:40. doi: 10.1186/s41927-020-00140-9
80. Maritati F, Corradi D, Versari A, Casali M, Urban ML, Buzio C, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis. 2012;71(7):1262-1264. doi: 10.1136/annrheumdis-2011-201166
81. Urban ML, Maritati F, Palmisano A, Fenaroli P, Peyronel F, Trivioli G, et al. Rituximab for chronic periaortitis without evidence of IgG4-related disease: A long-term follow-up study of 20 patients. Ann Rheum Dis. 2020;79(3):433-434. doi: 10.1136/annrheumdis-2019-216258
82. Wallwork R, Wallace Z, Perugino C, Sharma A, Stone JH. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). 2018;97(42):e12631. doi: 10.1097/MD.0000000000012631
83. Goni E, Vikse J, Lanzillotta M, Fevang BS, Midtvedt Ø, Mahajne J, et al. Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: A European multicenter cohort study. Eur J Intern Med. 2026;143:106459. doi: 10.1016/j.ejim.2025.106459
84. Zongfei J, Lijuan Z, Ying S, Dongmei L, Sifan W, Xiufang K, et al. Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: Insights from a prospective IgG4-related disease registry. Ther Adv Chronic Dis. 2021;12:20406223211028776
85. Cao X, Li S, Wan J, Yu Z, Dong G, Zhou W. Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2024;42(9):17361743. doi: 10.55563/clinexprheumatol/61mt03
86. Vaglio A, Catanoso MG, Spaggiari L, Magnani L, Pipitone N, Macchioni P, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. 2013;65(9):2469-2475. doi: 10.1002/art.38032
87. Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al.; MITIGATE Trial Investigators. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025;392(12):1168-1177. doi: 10.1056/NEJMoa2409712
88. Masamune A, Nishimori I, Kikuta K, Tsuji I, Mizuno N, Iiyama T, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66(3):487-494. doi: 10.1136/gutjnl-2016-312049.
Рецензия
Для цитирования:
Веретенников А.С., Торгашина А.В. Ретроперитонеальный фиброз: современный взгляд на старую патологию или когда вопросов больше, чем ответов. Научно-практическая ревматология. 2026;64(2):133-140. https://doi.org/10.47360/1995-4484-2026-133-140
For citation:
Veretennikov A.S., Torgashina A.V. Retroperitoneal fibrosis: A contemporary perspective on an old disease, or when there are more questions than answers. Rheumatology Science and Practice. 2026;64(2):133-140. (In Russ.) https://doi.org/10.47360/1995-4484-2026-133-140
Просмотров:
214
JATS XML
Послать статью по эл. почте 